Relpax Shortage: What Providers and Prescribers Need to Know in 2026

If your migraine patients are reporting difficulty filling eletriptan (Relpax) prescriptions, they're not alone — and the causes are worth understanding as their prescriber. While eletriptan is not on the FDA's official drug shortage list as of 2026, real-world availability challenges are creating friction for patients trying to fill prescriptions at retail pharmacies.

This briefing covers what you need to know about the current eletriptan landscape, including formulary changes, clinical considerations for switching, and tools to help your patients access their medication.

Current Availability Status

Eletriptan hydrobromide is not listed on the FDA's drug shortage database as of early 2026. National supply from generic manufacturers (including Aurobindo Pharma) appears stable. However, retail-level availability is inconsistent due to the following:

Formulary exclusion of brand Relpax: Most major commercial plans and PBMs have excluded brand-name Relpax (marking it "E" — excluded) from their 2026 formularies. Generic eletriptan hydrobromide is generally on Tier 1 or Tier 2 without prior authorization.

Low retail demand: Eletriptan is a lower-volume generic compared to sumatriptan. Many chain pharmacies minimize stock for low-volume items, leading to out-of-stock events.

Quantity limits (QL): Most payers apply quantity limits to triptans — typically 6–9 tablets per 30-day fill. Prescriptions written for larger quantities may be denied at the pharmacy level, which patients sometimes interpret as a stock problem.

Eletriptan's Clinical Position in 2026

Eletriptan 40mg continues to hold the strongest efficacy profile among oral triptans in comparative network meta-analyses. Key clinical data points to keep in mind:

Pain freedom at 2 hours: 37% (highest among oral triptans)

Pain relief at 2 hours: 60% (highest among oral triptans)

Half-life: ~4 hours — moderate duration, intermediate recurrence rate

CYP3A4 substrate: contraindicated within 72 hours of potent CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, nefazodone)

Max daily dose: 80mg (two 40mg doses, separated by at least 2 hours)

Insurance and Formulary Landscape in 2026

When prescribing eletriptan in the current environment, consider the following:

Always prescribe generic eletriptan hydrobromide rather than brand Relpax, unless a patient specifically requests brand and can pay cash. Most 2026 formularies cover the generic on Tier 1–2; the brand is excluded.

Most plans apply quantity limits of 6–9 tablets per 30 days. If your patient has frequent migraines requiring more, document medical necessity or consider a preventive therapy add-on.

Generic eletriptan typically does not require prior authorization on most commercial plans. Brand Relpax would require a formulary exception request.

Clinical Alternatives When Eletriptan Is Truly Unavailable

If a patient cannot locate eletriptan at any nearby pharmacy, the following bridge options should be considered:

Rizatriptan (Maxalt generic): Fastest-acting oral triptan; widely available generic; 33% pain freedom at 2 hours. Good bridge option for most patients.

Sumatriptan (Imitrex generic): Most widely stocked and cheapest triptan. Available in oral, nasal, and injectable forms. Strong second-line option.

Ubrogepant (Ubrelvy) or rimegepant (Nurtec ODT): For patients with cardiovascular contraindications to triptans or triptan non-responders. Prior authorization may be required; gepants are significantly more expensive without insurance.

How to Help Patients Find Eletriptan in Stock

Recommending medfinder for providers can be a practical resource to share with patients. medfinder calls pharmacies near the patient to check stock, then sends results by text — eliminating the need for patients to make multiple phone calls themselves. It works for any medication, including eletriptan.

For a detailed patient handout approach, see our guide on how to help your patients find Relpax in stock.